

Radius Health, Inc.  
Form 3  
June 13, 2014

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

<p>1. Name and Address of Reporting Person *</p> <p>Â F2 Bioscience VI L.P.</p> <p>(Last) (First) (Middle)</p> <p>PO BOX 309, UGLAND HOUSE,Â SOUTH CHURCH STREET</p> <p>(Street)</p> <p>GEORGE TOWN,Â E9Â KY1-1104</p> <p>(City) (State) (Zip)</p>	<p>2. Date of Event Requiring Statement</p> <p>(Month/Day/Year)</p> <p>06/11/2014</p>	<p>3. Issuer Name and Ticker or Trading Symbol</p> <p>Radius Health, Inc. [RDUS]</p>	<p>4. Relationship of Reporting Person(s) to Issuer</p> <p>(Check all applicable)</p> <p><input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below)</p>	<p>5. If Amendment, Date Original Filed(Month/Day/Year)</p>	<p>6. Individual or Joint/Group Filing(Check Applicable Line)</p> <p><input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person</p>
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	587,500	D <sup>(1)</sup>	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
-----------------------------------------------	-------------------------------------------------------------	--------------------------------------------------------------------------------	-----------------------------------------------	-------------------------------------------	----------------------------------------------------------

Edgar Filing: Radius Health, Inc. - Form 3

Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)
---------------------	--------------------	-------	----------------------------------	----------	------------------------------------------------

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
F2 Bioscience VI L.P. PO BOX 309, UGLAND HOUSE SOUTH CHURCH STREET GEORGE TOWN, KY1-1104	^	^ X	^	^
F2 Capital Ltd 3RD FLOOR, GENEVE PLACE, WATERFRONT DR PO BOX 3175, ROAD TOWN TORTOLA, D8	^	^ X	^	^
Priestley Katherine SUITE 6, ALBION RIVERSIDE BUILDING 8 HESTER ROAD LONDON, X0 SW11 4AX	^	^ X	^	^
Globeways Holdings Ltd 3RD FLOOR, GENEVE PLACE, WATERFRONT DR PO BOX 3175, ROAD TOWN TORTOLA, D8	^	^ X	^	^
F2 Bioscience IV GP Ltd. PO BOX 309, UGLAND HOUSE SOUTH CHURCH STREET GEORGE TOWN, KY1-1104	^	^ X	^	^

## Signatures

/s/ Morag Law, attorney-in-fact for F2 Bioscience VI, L.P.	06/12/2014
__Signature of Reporting Person	Date
/s/ Morag Law, attorney-in-fact for F2 Bioscience IV GP Ltd.	06/12/2014
__Signature of Reporting Person	Date
/s/ Morag Law, attorney-in-fact for F2 Capital Ltd.	06/12/2014
__Signature of Reporting Person	Date
/s/ Morag Law, attorney-in-fact for Katherine Priestley	06/12/2014
__Signature of Reporting Person	Date
/s/ Morag Law, attorney-in-fact for Globeways Holdings Ltd.	06/12/2014
__Signature of Reporting Person	Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The reported securities are owned directly by F2 Bioscience VI L.P. ("F2 Science"). F2 Bioscience IV GP Ltd. ("F2 IV GP") is the General Partner of F2 Science. Katherine Priestley and Globeways Holdings Limited are members of F2 IV GP. F2 Capital Limited is an

(1) investment adviser to F2 Science. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.